when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

insulin · news · pharmadog

← back to insulin

News mentioning insulin

66 stories

20hFDA greenlights Abbott’s wearable sensor for capturing diabetic ketoacidosisfiercebiotech

23hInside the Gulf biotech deal model, ahead of RGMBS 2026 in Riyadhbiospace

8dNovo takes first round of oral obesity duel. Can it stay ahead of Lilly?biospace

8dSTAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and morestat

8dAmylyx’s bet on a GLP-1 blocker pays offbiopharma dive

8dAmylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemiabiospace

9dSTAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and morestat

9dSTAT+: Kennedy’s split-screen week: Talk of vaccines in D.C., fraud and addiction out Weststat

12dSTAT+: Up and down the ladder: The latest comings and goingsstat

12dSTAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and morestat

12dSTAT+: Drug-testing lab that has sparked controversy sues group that develops drug standards over criticismstat

12dTwo years after rules overhaul, have methadone clinics really changed?stat

13dSTAT+: Eli Lilly targets booming black market for retatrutidestat

13dSTAT+: Kennedy heads west, slams Becerrastat

13dSTAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and morestat

13dSTAT+: Newsom promotes affordable insulin, but California’s generic label is off to a slow startstat

13dSTAT+: As young people increasingly get cancer, new fertility options are changing their futuresstat

13dSTAT+: What patients actually think about ‘minimally invasive’ brain implantsstat

14dPfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pillfiercebiotech

16dAbbott teams with Google Health on AI-powered health insights appfiercebiotech

20dBioVie shares halve on murky Parkinson’s disease readoutbiospace

22dSTAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and morestat

22dSTAT+: The latest orphan drug exemptions may not be warranted, analysis findsstat

22dOpinion: I’m using not-FDA-approved software to manage my diabetes. I’ve never felt betterstat

23dSTAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate casestat

23dSTAT+: Is there a pharma mega-merger in the making?stat

23dSTAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and morestat

23dSTAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with statesstat

23dSTAT+: Are AI scribes useful tools in medical education, or a crutch that imperils learning?stat

24dSTAT+: Michigan Supreme Court ruling allows probe into Lilly insulin pricingstat

← prevpage 1 of 3next →